Obio Technology Shanghai Corp Ltd
SSE:688238
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.02
12.32
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Obio Technology Shanghai Corp Ltd stock under the Base Case scenario is 3.8 CNY. Compared to the current market price of 4.05 CNY, Obio Technology Shanghai Corp Ltd is Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Obio Technology Shanghai Corp Ltd
Run backtest to discover the historical profit from buying and selling Obio Technology Shanghai Corp Ltd based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Obio Technology Shanghai Corp Ltd
Balance Sheet Decomposition
Obio Technology Shanghai Corp Ltd
Current Assets | 927.4m |
Cash & Short-Term Investments | 653m |
Receivables | 183.1m |
Other Current Assets | 91.4m |
Non-Current Assets | 1.7B |
Long-Term Investments | 107.5m |
PP&E | 1.4B |
Intangibles | 55.5m |
Other Non-Current Assets | 88m |
Current Liabilities | 314.2m |
Accounts Payable | 228.5m |
Accrued Liabilities | 21.5m |
Other Current Liabilities | 64.2m |
Non-Current Liabilities | 231.1m |
Long-Term Debt | 172.8m |
Other Non-Current Liabilities | 58.3m |
Earnings Waterfall
Obio Technology Shanghai Corp Ltd
Revenue
|
233.6m
CNY
|
Cost of Revenue
|
-255.9m
CNY
|
Gross Profit
|
-22.3m
CNY
|
Operating Expenses
|
-161.5m
CNY
|
Operating Income
|
-183.7m
CNY
|
Other Expenses
|
45.4m
CNY
|
Net Income
|
-138.4m
CNY
|
Free Cash Flow Analysis
Obio Technology Shanghai Corp Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Obio Technology Shanghai Corp Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Obio Technology Shanghai Corp Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Obio Technology Shanghai Corp Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Obio Technology Shanghai Corp Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Obio Technology Shanghai Corp Ltd
According to Wall Street analysts, the average 1-year price target for Obio Technology Shanghai Corp Ltd is 8.36 CNY with a low forecast of 8.28 CNY and a high forecast of 8.61 CNY.
Shareholder Yield
Current shareholder yield for Obio Technology Shanghai Corp Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Price
Obio Technology Shanghai Corp Ltd
Average Annual Return | -7.76% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -85% |
Market Capitalization | 2.6B CNY |
Shares Outstanding | 647 433 024 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one Obio Technology Shanghai Corp Ltd stock under the Base Case scenario is 3.8 CNY.
Compared to the current market price of 4.05 CNY, Obio Technology Shanghai Corp Ltd is Overvalued by 6%.